γ-Heavy Chain Disease
Authors:
- Thomas E. WitzigTWThomas E. Witzig
- Laura L. LoehrerLLLaura L. Loehrer
- Robert A. KyleRKRobert A. Kyle
- 1 July 2003
- journal article
- case report
- Published by Wolters Kluwer Health in Medicine
- Vol. 82 (4) , 236-250
Abstract
We report the cases of 23 patients with γ-heavy chain disease seen at our institution (8 patients previously reported, 15 new patients). There were 15 women and 8 men; the median age at diagnosis was 68 years (range, 42–87 yr). Sixteen patients had an associated lymphoplasma cell proliferative disorder, 3 had a lymphoplasma cell proliferative disorder and an autoimmune disorder, another 3 had an autoimmune disorder only, and 1 had no underlying disease. The lymphoplasma cell proliferative disorder was disseminated in 10 patients and localized in 6. Patients with localized lymphoplasma cell proliferative disorder included 3 with plasmacytoma (1 tongue, 1 submandibular area, and 1 thyroid), 2 with lymphoplasma cell proliferative disorder involving the bone marrow only, and 1 with amyloid of the skin. At the time of diagnosis, lymphadenopathy was present in 8 patients, splenomegaly in 7, and hepatomegaly in 1. A monoclonal spike on serum protein electrophoresis was documented in 19 patients. γ-Heavy chain was documented by immunofixation in the serum of all patients; 2 had an additional immunoglobulin M-λ. γ-Heavy chain was present in the urine in 19 of 22 patients. Sixteen patients were treated for lymphoplasma cell proliferative disorder or autoimmune disorder (14 with chemotherapy, 1 splenectomy, and 1 thyroidectomy followed by radiation therapy). For 5 patients, treatment was not felt to be necessary; 2 patients were thought to be too sick for treatment. Of the 16 patients treated, 6 had a complete clinical response (in 2, γ-heavy chain disappeared; in 2, γ-heavy chain persisted; and for 2, no serologic follow-up was available); in 10 patients, clinical disease persisted (in 3, γ-heavy chain disappeared; in 6, it persisted; and for 1, no serologic follow-up was available). Of 7 patients not treated, 2 died within 5 months; 1 died after 15 months; 2 had no clinical disease at latest follow-up, although γ-heavy chain persisted; and 2 had no change in clinical and serologic status. The median duration of follow-up was 33 months (range, 1–261 mo). Median survival was 7.4 years.Keywords
This publication has 35 references indexed in Scilit:
- HEAVY-CHAIN DISEASESHematology/Oncology Clinics of North America, 1999
- GAMMA HEAVY CHAIN DISEASE DEVELOPING IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROMEBritish Journal of Haematology, 1992
- Gamma heavy chain disease associated with Hodgkin' disease. Clinical, pathologic, and immunologic features of one caseCancer, 1990
- Gamma heavy chain disease and rheumatoid arthritisSeminars in Arthritis and Rheumatism, 1989
- A New Case of γ‐Heavy Chain DiseaseScandinavian Journal of Haematology, 1982
- Diagnosis of Gamma Heavy-Chain DiseaseAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1981
- A case of gamma 3 heavy chain disease with vacuolated plasma cells: a clinical, immunological, and ultrastructural study.Journal of Clinical Pathology, 1979
- Gamma heavy chain disease simulating alpha chain disease.Gut, 1978
- An unusual case of a plasma cell neoplasm with an IgG3lambda myeloma and a gamma3 heavy chain disease proteinBlood, 1978
- Gamma heavy chain disease: clinical aspects and characterization of a deleted, noncovalently linked gamma1 heavy chain dimer (BAZ)Blood, 1977